AIM: The severity of atherosclerosis is primarily determined by overall lipid metabolism and the degree of inflammation present within the vessel wall. We evaluated the effects of T-0901317, a liver X receptor agonist, on the atherosclerosis process, and especially on the endothelial function in ApoE(-/-) mice. METHODS AND RESULTS: ApoE(-/-) mice were treated with LXR agonist T-0901317 (1 μmol/L) for 6 weeks. ApoE(-/-) mice receiving T-0901317 were found to have markedly improved overall serum lipid profiles, albeit increased serum triglycerides. MRI imaging demonstrated that T-0901317 attenuated the atherosclerotic plaque burden in the aorta of ApoE(-/-) mice. Transmission electron microscopy and immunohistochemistry revealed attenuated ultrastructural changes as well as enhanced expression of the ATP-binding cassette transporter ABCA1. In addition, treatment with the LXR agonist improved the vasomotor function of atherosclerotic arteries, as assessed by KCl/norepinephrine-induced vasoconstrictive and acetylcholine-induced vasorelaxation functional assays. In vitro studies showed increased ABCG1, phospho-Akt and phospho-eNOS expression in ApoE(-/-) mice aorta endothelial cells (ECs) after T0901317 treatment. CONCLUSION: The present study suggest that LXR agonists protect the endothelium against atherosclerotic insults by increasing ABCA1 and ABCG1 expression, and improve the endothelial-dependent vasomotor function probably by promoting Akt and eNOS phosphorylation.
AIM: The severity of atherosclerosis is primarily determined by overall lipid metabolism and the degree of inflammation present within the vessel wall. We evaluated the effects of T-0901317, a liver X receptor agonist, on the atherosclerosis process, and especially on the endothelial function in ApoE(-/-) mice. METHODS AND RESULTS: ApoE(-/-) mice were treated with LXR agonist T-0901317 (1 μmol/L) for 6 weeks. ApoE(-/-) mice receiving T-0901317 were found to have markedly improved overall serum lipid profiles, albeit increased serum triglycerides. MRI imaging demonstrated that T-0901317 attenuated the atherosclerotic plaque burden in the aorta of ApoE(-/-) mice. Transmission electron microscopy and immunohistochemistry revealed attenuated ultrastructural changes as well as enhanced expression of the ATP-binding cassette transporter ABCA1. In addition, treatment with the LXR agonist improved the vasomotor function of atherosclerotic arteries, as assessed by KCl/norepinephrine-induced vasoconstrictive and acetylcholine-induced vasorelaxation functional assays. In vitro studies showed increased ABCG1, phospho-Akt and phospho-eNOS expression in ApoE(-/-) mice aorta endothelial cells (ECs) after T0901317 treatment. CONCLUSION: The present study suggest that LXR agonists protect the endothelium against atherosclerotic insults by increasing ABCA1 and ABCG1 expression, and improve the endothelial-dependent vasomotor function probably by promoting Akt and eNOS phosphorylation.
Authors: Sean B Joseph; Elaine McKilligin; Liming Pei; Michael A Watson; Alan R Collins; Bryan A Laffitte; Mingyi Chen; Grace Noh; Joanne Goodman; Graham N Hagger; Jonathan Tran; Tim K Tippin; Xuping Wang; Aldons J Lusis; Willa A Hsueh; Ronald E Law; Jon L Collins; Timothy M Willson; Peter Tontonoz Journal: Proc Natl Acad Sci U S A Date: 2002-05-28 Impact factor: 11.205
Authors: Margarita de la Llera-Moya; Denise Drazul-Schrader; Bela F Asztalos; Marina Cuchel; Daniel J Rader; George H Rothblat Journal: Arterioscler Thromb Vasc Biol Date: 2010-01-14 Impact factor: 8.311
Authors: Radosveta P Koldamova; Iliya M Lefterov; Matthias Staufenbiel; Darren Wolfe; Shaohua Huang; Joseph C Glorioso; Michael Walter; Michael G Roth; John S Lazo Journal: J Biol Chem Date: 2004-11-22 Impact factor: 5.157
Authors: Adelheid Kratzer; Marlene Buchebner; Thomas Pfeifer; Tatjana M Becker; Georg Uray; Makoto Miyazaki; Shinobu Miyazaki-Anzai; Birgit Ebner; Prakash G Chandak; Rajendra S Kadam; Emine Calayir; Nora Rathke; Helmut Ahammer; Branislav Radovic; Michael Trauner; Gerald Hoefler; Uday B Kompella; Guenter Fauler; Moshe Levi; Sanja Levak-Frank; Gerhard M Kostner; Dagmar Kratky Journal: J Lipid Res Date: 2008-09-23 Impact factor: 5.922
Authors: Lars Verschuren; Jitske de Vries-van der Weij; Susanne Zadelaar; Robert Kleemann; Teake Kooistra Journal: J Lipid Res Date: 2008-08-30 Impact factor: 5.922
Authors: Ronald J van der Sluis; Joya E Nahon; Anne Q Reuwer; Miranda Van Eck; Menno Hoekstra Journal: Br J Pharmacol Date: 2015-03-16 Impact factor: 8.739